Hoda Abdel-Aty ๐Ÿ’™ (@hoda_aty) 's Twitter Profile
Hoda Abdel-Aty ๐Ÿ’™

@hoda_aty

Research Fellow @ICR_London @royalmarsdenNHS | #STAMPEDE2 trial fellow @MRCCTU @UCL | ST7 Clinical Oncology Registrar | Co-host @TrialsTribsPod | Views my own

ID: 737032387821985792

calendar_today29-05-2016 21:26:29

140 Tweet

390 Followers

1,1K Following

Gerry Hanna (@gerryhanna) 's Twitter Profile Photo

Are you a clinican involved in treating patients with breast cancer? If yesโ“- please consider completing this survey on the potential role of #SABR / #SBRT in patients with non-localised breast cancer โฌ‡๏ธ ๐Ÿ”—forms.office.com/e/DVp7uQYrPj

Are you a clinican involved in treating patients with breast cancer?

If yesโ“- please consider completing this survey on the potential role of #SABR / #SBRT in patients with non-localised breast cancer โฌ‡๏ธ

๐Ÿ”—forms.office.com/e/DVp7uQYrPj
UCL Population Health Sciences (@uclpophealthsci) 's Twitter Profile Photo

Congratulations to the ICTM at UCL Director, Max Parmar, who has been awarded the Royal Statistical Society's 2024 Bradford Hill Medal!๐Ÿ…๐Ÿ‘ Max has been recognised for his innovative work on efficient designs for late-phase #ClinicalTrials. Read more โฌ‡๏ธ ucl.ac.uk/population-heaโ€ฆ

Nick James (@prof_nick_james) 's Twitter Profile Photo

Latest episode of "Trials and tribulations" has an interview with silke gillessen about the forthcoming #STAMPEDE metformin analysis plus discussion about trial regulation repurposing studies and barriers to access for routine data MRC Clinical Trials Unit at UCL The ICR Trials & Tribulations | Oncology Trials Podcast

Sukhi Nagpal (@sukhinagpal) 's Twitter Profile Photo

If you are an oncologist or surgeon who refers or treats oligometastatic breast cancer please kindly take a moment to fill out our survey! All responses are immensely valued globally! #breastcancer #SBRT #SABR #bcsm forms.office.com/e/DVp7uQYrPj

Chris Parker (@pcaparker) 's Twitter Profile Photo

Good to see RADICALS-HD in print. THanks to numerous colleagues and collaborators over 20 years authors.elsevier.com/sd/article/S01โ€ฆ

Drew Moghanaki ๐Ÿ• (@drewmoghanaki) 's Twitter Profile Photo

With ASTRO elections coming up this week, why do so many members think Neha Vapiwala deserves our vote to be the next President? For starters, former ASTRO presidents and gold medal winners have concurred she is one of the most inclusive and effective leaders to ever run for

With ASTRO elections coming up this week, why do so many members think <a href="/NehaVapiwala/">Neha Vapiwala</a> deserves our vote to be the next President? For starters, former <a href="/ASTRO_org/">ASTRO</a> presidents and gold medal winners have concurred she is one of the most inclusive and effective leaders to ever run for
Matthias Guckenberger (@mat_guc) 's Twitter Profile Photo

THE highlight before summer break Virtual Grand Rounds in Radiation Oncology Prof. Chris Parker presenting and discussing RADICALS-HD trials Tuesday July 16th 17:00 - 17:30 CEST Registration ๐Ÿ‘‡ usz.ch/veranstaltungeโ€ฆ

THE highlight before summer break
Virtual Grand Rounds in Radiation Oncology 

Prof. Chris Parker 
presenting and discussing 
RADICALS-HD trials

Tuesday July 16th 
17:00 - 17:30 CEST

Registration ๐Ÿ‘‡
usz.ch/veranstaltungeโ€ฆ
Nick James (@prof_nick_james) 's Twitter Profile Photo

International collaboration in trials should be a no brainer - faster recruitment, broader representation of health care systems and expertise, etc. Why then is it relatively rare? Latest episode of Trials & Tribulations | Oncology Trials Podcast discusses this with Neha Vapiwala open.spotify.com/episode/5yEDdkโ€ฆ

Nick James (@prof_nick_james) 's Twitter Profile Photo

How should we do Phase 1 trials in the era of targeted therapies, immune therapies and bispecific drug conjugates. Is the traditional 3+3 model irrelevant? How do we do pharmacokinetics? Listen to Phase 1 trial maestro udaibanerji in our latest episode. open.spotify.com/episode/1sQdZXโ€ฆ

Nick James (@prof_nick_james) 's Twitter Profile Photo

STAMPEDE2 now up and running. Patient reported outcomes are key to sucessful trials and current tools may not reflect patient needs and issues. As part of our QOL programme for STAMPEDE2 we have reviewed this with our patient representatives. sciencedirect.com/science/articlโ€ฆ

MRC Clinical Trials Unit at UCL (@mrcctu) 's Twitter Profile Photo

#ESMO24 begins this Friday and we will be presenting the latest findings from our PATCH, STAMPEDE and STAMPEDE2 #ClinicalTrials in #ProstateCancer. ๐Ÿ“Are you attending? We've put together a helpful guide to all our presentations and posters๐Ÿ‘‡ mrcctu.ucl.ac.uk/news/news-storโ€ฆ

#ESMO24 begins this Friday and we will be presenting the latest findings from our PATCH, STAMPEDE and STAMPEDE2 #ClinicalTrials in #ProstateCancer.  

๐Ÿ“Are you attending? We've put together a helpful guide to all our presentations and posters๐Ÿ‘‡

mrcctu.ucl.ac.uk/news/news-storโ€ฆ